ABSTRACT
Background Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A subset of SSc patients harbor autoantibodies against the M2 mitochondrial antigen (AM2A). Here, we investigate whether M2 is expressed by specific ENS cells, and if AM2A associate with GI dysmotility in SSc patients.
Methods Sera from 154 well-characterized patients with SSc were screened for AM2A by ELISA. Clinical features and GI transit data were compared between AM2A-positive and negative patients. HepG2 cells were cultured with these sera and co-stained with AM2A.
Results Nineteen of 147 patients (12.9%) were AM2A positive. AM2A positivity was significantly associated with slower transit in the esophagus (β -14.4, 95%CI -26.2, -2.6) and stomach (β -7.9, 95% CI -14.1, -1.6). Immunostaining demonstrated pan-mitochondrial antigens TOM-20 and M2 enrichment in human ENS neurons, specifically in mesoderm- derived enteric neurons (MENS). HepG2 cells cultured with SSc sera showed that SSc autoantibodies penetrate live cells and that AM2A and other SSc autoantibodies are localized to subcellular compartments containing target antigens.
Conclusion AM2A in SSc patients associate with slower GI transit. MENs are enriched in mitochondria, suggesting enhanced susceptibility to mitochondrial dysfunction and associated GI dysmotility in SSc. Our finding that SSc autoantibodies penetrate live cells in vitro suggests that SSc-AM2A may penetrate MENs in vivo, driving ENS and GI dysfunction. Further studies are warranted to understand whether AM2As contribute to mitochondrial dysfunction, and whether mitochondrial dysfunction contributes to GI dysmotility in SSc.
Key messages
What is already known on this topic
subset of SSc patients have autoantibodies against the M2 mitochondrial antigen (AM2A). Whether AM2A antibodies inform the presence or severity of GI dysfunction in SSc is unknown.
What this study adds:
AM2A antibodies in SSc patients associate with slower upper GI transit.
Mitochondria are enriched in a recently identified mesoderm-derived lineage of enteric neurons (MENs), which play a major role in GI motility. This suggests that MENS may be more mitochondrial-dependent than other cell types, and thus more susceptible to mitochondrial dysfunction. This may contribute to dysmotility in AM2A-positive SSc patients.
SSc autoantibodies penetrate live cells in vitro and bind to their target antigens intracellularly.
How this study might affect research, practice or policy
AM2A antibodies in SSc patients may penetrate MENs in vivo, driving ENS dysfunction and subsequent GI dysmotility
This potentially novel mechanism in SSc GI disease could inform our current approach to diagnosing and managing these patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funding from NIAMS R01 AR081382-01A1 (ZM), the Rheumatology Research Foundation and Scleroderma Research Foundation (ZM), NIA R0AG166768, DIACOMP pilot funding, and pilot and feasibility grant from Harvard Digestive Disease Core (all three to SK), R01 AR073208 (LCR), and the Donald B. and Dorothy L. Stabler Foundation. The Rheumatic Diseases Research Core Center, where the ELISA assays were performed, is supported by NIH P30-AR070254.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Gastrointestinal Assessment Protocol (GAP) Cohort is a prospectively enrolled National Institutes of Health (NIH) sponsored GI cohort of well characterized patients with SSc from the Johns Hopkins Scleroderma Center. It includes a subset of the Johns Hopkins Scleroderma Center Research Registry. Patients were consecutively recruited during routine clinical visits from July 2016 to April 2022 if they met either the 2013 American College of Rheumatology (ACR)/EULAR criteria for SSc or had at least three of the five features of CREST syndrome. During routine clinical visits the treating physician (rheumatologist or gastroenterologist) screened for significant symptoms of GI dysfunction. Patients with significant upper GI disease or lower and upper GI dysfunction symptoms who agreed to complete a whole gut transit study were included. The Johns Hopkins Institutional Review Board approved all human patient protocols and all individuals signed written informed consent. Paraffin sections of the adult small intestinal full-thickness gut from deidentified human tissues were obtained from the Department of Pathology at Beth Israel Deaconess Medical Center and the Institutional Review Board approved using the deidentified human tissues.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.